Azopt(brinzolamide)
Azarga, Azopt, Brinzolamide, Simbrinza (brinzolamide) is a small molecule pharmaceutical. Brinzolamide was first approved as Azopt on 1998-04-01. It is used to treat open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension and open-angle glaucoma. The pharmaceutical is active against carbonic anhydrase 7. In addition, it is known to target carbonic anhydrase 12, carbonic anhydrase 14, and carbonic anhydrase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
Azopt, Brinzolamide
CombinationsSimbrinza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Brimonidine tartrate
+
Brinzolamide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SIMBRINZA | Alcon Research | N-204251 RX | 2013-04-19 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| azopt | New Drug Application | 2023-11-24 |
| brinzolamide | ANDA | 2024-07-10 |
| simbrinza | New Drug Application | 2025-03-11 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
73 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | D005901 | EFO_0000516 | H40 | 1 | 6 | 20 | 31 | 5 | 62 |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | 1 | 6 | 17 | 18 | 5 | 46 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 5 | 13 | 15 | 3 | 36 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 6 | 16 | 11 | 2 | 35 |
| Intraocular pressure | D007429 | — | — | — | — | — | 1 | 2 | 3 |
| Angle-closure glaucoma | D015812 | — | — | — | — | 2 | 1 | — | 3 |
| Capsule opacification | D058442 | — | H26.4 | — | — | — | 1 | — | 1 |
| Low tension glaucoma | D057066 | EFO_1001022 | H40.12 | — | — | — | 1 | — | 1 |
| Syndrome | D013577 | — | — | — | — | — | 1 | — | 1 |
| Congenital nystagmus | D020417 | EFO_0007217 | H55.01 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal dystrophies | D058499 | Orphanet_71862 | — | — | 1 | — | — | — | 1 |
| Central serous chorioretinopathy | D056833 | — | H35.71 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exfoliation syndrome | D017889 | EFO_0004235 | — | — | — | — | — | 2 | 2 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | — | — | — | 1 | 1 |
| Myopia | D009216 | EFO_0003927 | H52.1 | — | — | — | — | 1 | 1 |
| Cataract | D002386 | EFO_0001059 | H26.9 | — | — | — | — | 1 | 1 |
| Retinoschisis | D041441 | — | H33.10 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Brinzolamide |
| INN | brinzolamide |
| Description | Brinzolamide is a sulfonamide and a thienothiazine. It has a role as an antiglaucoma drug and an EC 4.2.1.1 (carbonic anhydrase) inhibitor. |
| Classification | Small molecule |
| Drug class | carbonic anhydrase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21 |
Identifiers
| PDB | — |
| CAS-ID | 138890-62-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL220491 |
| ChEBI ID | 3176 |
| PubChem CID | 68844 |
| DrugBank | DB01194 |
| UNII ID | 9451Z89515 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CA2
CA2
Organism
Homo sapiens
Gene name
CA2
Gene synonyms
NCBI Gene ID
Protein name
carbonic anhydrase 2
Protein synonyms
CA-II, CAC, Carbonate dehydratase II, carbonic anhydrase B, Carbonic anhydrase C, Carbonic anhydrase II, carbonic dehydratase, Cyanamide hydratase CA2, epididymis luminal protein 76, epididymis secretory protein Li 282
Uniprot ID
Mouse ortholog
Car2 (12349)
carbonic anhydrase 2 (Q9DCY9)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Brinzolamide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,708 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,516 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use